Intarcia Therapeutics

About:

Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.

Website: http://www.intarcia.com

Twitter/X: intarcia

Top Investors: RA Capital Management, Fidelity, New Enterprise Associates, MidCap Financial, Horizon Technology Finance

Description:

Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity. David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.